Hepatitis B virus infection or reactivation and HBV-related liver dysfunction in patients with inflammatory bowel disease receiving infliximab: a nationwide real-world study
MedScience · 2026-04 · 20 (2) · 301-310
DOI: 10.1007/s11684-026-1208-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift MedScience, online erschienen am 06.05.2026. Verfasst von Rongbei Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. liurongbei@zju.edu.cn. Hauptthemen laut MEDLINE: Infliximab, Inflammatory Bowel Diseases, Virus Activation, Hepatitis B virus. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Infliximab (IFX) for inflammatory bowel disease (IBD) treatment may increase the risk of hepatitis B virus (HBV) reactivation, particularly in areas with high HBV prevalence such as China. This study aimed to evaluate HBV reactivation/infection, liver dysfunction, vaccination efficacy and strategies in IBD patients undergoing IFX therapy. This retrospective, multicenter study included 4183 IBD patients from 15 hospitals across China, who were divided into six groups according to the HBV status. Demographic features, HBV vaccination status, reactivation/infection rates, and liver dysfunction outcomes were collected, with data collection performed from 2009 to 2022. We found that HBV reactivation rate was notably higher in HBsAg positive group than other groups ( P < 0.05) despite antiviral treatment. Although only 29% of patients were immunized at IFX initiation and almost no patients got vaccinated against HBV during IFX treatment, no patients experienced HBV infection in the susceptible population group. The study underscores a critical need for rigorous HBV screening before IFX initiation. Despite antiviral prophylaxis, the importance of continuous monitoring of HBV DNA is necessary for HBsAg positive patients. HBsAg negative patients, including the susceptible population, had a very low risk of new HBV infection, thus reassuring patients and physicians of the safety of IFX in this cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. liurongbei@zju.edu.cn.
- Center of Inflammatory Bowel Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. liurongbei@zju.edu.cn.
- Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
- Center of Inflammatory Bowel Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
- Department of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, 510655, China.
Zitieren
APA
Liu, R., Wu, T., Tang, J., Zhang, H., Fan, Y., Sun, H., Xie, C., Zhou, Q., Xu, H., Zhu, Y., Ye, M., Shi, X., Tian, F., Shen, H., Xu, D., Zhou, Y., & Cao, Q. (2026). Hepatitis B virus infection or reactivation and HBV-related liver dysfunction in patients with inflammatory bowel disease receiving infliximab: a nationwide real-world study. MedScience, 20(2), 301-310. https://doi.org/10.1007/s11684-026-1208-0
Vancouver
Liu R, Wu T, Tang J, Zhang H, Fan Y, Sun H, et al. Hepatitis B virus infection or reactivation and HBV-related liver dysfunction in patients with inflammatory bowel disease receiving infliximab: a nationwide real-world study. MedScience. 2026;20(2):301-310. doi:10.1007/s11684-026-1208-0
BibTeX
@article{Liu2026,
author = {Liu, Rongbei and Wu, Tingting and Tang, Jian and Zhang, Hongjie and Fan, Yanyun and Sun, Haibo and Xie, Chen and Zhou, Qunyan and Xu, Hongzhen and Zhu, Yabi and Ye, Mei and Shi, Xiaomin and Tian, Feng and Shen, Haiyan and Xu, Dan and Zhou, Ying and Cao, Qian},
title = {Hepatitis B virus infection or reactivation and HBV-related liver dysfunction in patients with inflammatory bowel disease receiving infliximab: a nationwide real-world study},
journal = {MedScience},
year = {2026},
volume = {20},
number = {2},
pages = {301--310},
doi = {10.1007/s11684-026-1208-0}
}
EUVIMED